About this medicine
- Approved name
- Adakveo
- International non-proprietary name (INN) or common name
- crizanlizumab
- Associated names
- Adakveo
- Class
- Other haematological agents
About this procedure
- Current status
- European Commission final decision
- Reference number
- EMEA/H/A-20/1525/C/4874/0013
- Type
- Article 20 procedures
This type of procedure is triggered for medicines that have been authorised via the centralised procedure in case of quality, safety or efficacy issues.
- Authorisation model
- Centrally authorised product(s)
- Decision making model
- CHMP-EC
Key dates and outcomes
- Procedure start date
- 26/01/2023
- CHMP opinion date
- 25/05/2023
- EC decision date
- 03/08/2023